Genetic and biochemical normalization in female carriers of duchenne muscular dystrophy: Evidence for failure of dystrophin production in dystrophin-competent myonuclei

E. Pegoraro, R. N. Schimke, C. Garcia, H. Stern, M. Cadaldini, C. Angelini, E. Barbosa, James Edwin Carroll, W. A. Marks, H. E. Neville, H. Marks, S. Appleton, H. Toriello, H. B. Wessel, J. Donnelly, S. M. Bernes, J. W. Taber, L. Weiss, E. P. Hoffman

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Article abstract-We studied 19 symptomatic female carriers of the Duchenne muscular dystrophy (DMD) gene. Most of these dystrophinopathy patients had had an erroneous or ambiguous diagnosis prior to dystrophin immunofluorescence testing. We assessed clinical severity by a standardized protocol, measured X-chromosome inactivation patterns in blood and muscle DNA, and quantitated the dystrophin protein content of muscle. We found that patients could be separated into two groups: those showing equal numbers of normal and mutant dystrophin genes in peripheral blood DNA ("random" X-inactivation), and those showing preferential use of the mutant dystrophin gene ("skewed" X-inactivation). In the random X-inactivation carriers, the clinical phenotype ranged from asymptomatic to mild disability, the dystrophin content of muscle was >60% of normal, and there were only minor histopathologic changes. In the skewed X-inactivation patients, clinical manifestations ranged from mild to severe, but the patients with mild disease were young (5 to 10 years old). The low levels of dystrophin (<30% on average) and the severe symptoms of the older patients suggested a poor prognosis for those with skewed X-inactivation, and they all showed morphologic changes of dystrophy. The random inactivation patients showed evidence of biochemical "normalization," with higher dystrophin content in muscle than predicted by the number of normal dystrophin genes. Seventy-nine percent of skewed X-inactivation patients (11/14) showed genetic "normalization," with proportionally more dystrophin-positive nuclei in muscle than in blood. In 65% of the skewed X-inactivation patients, dystrophin was not produced by dystrophin-positive nuclei; an average of 20% of myofiber nuclei were genetically dystrophin-positive but did not produce stable dystrophin. Biochemical normalization seems to be the main mechanism for rescue of fibers from dystrophin deficiency in the random X-inactivation patients. In the skewed X-inactivation patients, genetic normalization is active, but production failure of dystrophin by dystrophin-normal nuclei may counteract any effect of biochemical normalization. In the skewed X-inactivation patients, the remodeling of the muscle through cycles of degeneration and regeneration led to threefold increase in the number of dystrophin-competent nuclei in muscle myofibers (3.3 +-\4.6), while dystrophin content was on the average 1.5-fold less than expected (-1.54 +-\3.38). Our results permit more accurate prognostic assessment of isolated female dystrophinopathy patients and provide important data with which to estimate the potential effect of gene delivery (gene therapy) in DMD.

Original languageEnglish (US)
Pages (from-to)677-690
Number of pages14
JournalNeurology
Volume45
Issue number4
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Dystrophin
Duchenne Muscular Dystrophy
Molecular Biology
X Chromosome Inactivation
Muscles
Genes
Muscle Proteins
DNA

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Genetic and biochemical normalization in female carriers of duchenne muscular dystrophy : Evidence for failure of dystrophin production in dystrophin-competent myonuclei. / Pegoraro, E.; Schimke, R. N.; Garcia, C.; Stern, H.; Cadaldini, M.; Angelini, C.; Barbosa, E.; Carroll, James Edwin; Marks, W. A.; Neville, H. E.; Marks, H.; Appleton, S.; Toriello, H.; Wessel, H. B.; Donnelly, J.; Bernes, S. M.; Taber, J. W.; Weiss, L.; Hoffman, E. P.

In: Neurology, Vol. 45, No. 4, 01.01.1995, p. 677-690.

Research output: Contribution to journalArticle

Pegoraro, E, Schimke, RN, Garcia, C, Stern, H, Cadaldini, M, Angelini, C, Barbosa, E, Carroll, JE, Marks, WA, Neville, HE, Marks, H, Appleton, S, Toriello, H, Wessel, HB, Donnelly, J, Bernes, SM, Taber, JW, Weiss, L & Hoffman, EP 1995, 'Genetic and biochemical normalization in female carriers of duchenne muscular dystrophy: Evidence for failure of dystrophin production in dystrophin-competent myonuclei', Neurology, vol. 45, no. 4, pp. 677-690. https://doi.org/10.1212/WNL.45.4.677
Pegoraro, E. ; Schimke, R. N. ; Garcia, C. ; Stern, H. ; Cadaldini, M. ; Angelini, C. ; Barbosa, E. ; Carroll, James Edwin ; Marks, W. A. ; Neville, H. E. ; Marks, H. ; Appleton, S. ; Toriello, H. ; Wessel, H. B. ; Donnelly, J. ; Bernes, S. M. ; Taber, J. W. ; Weiss, L. ; Hoffman, E. P. / Genetic and biochemical normalization in female carriers of duchenne muscular dystrophy : Evidence for failure of dystrophin production in dystrophin-competent myonuclei. In: Neurology. 1995 ; Vol. 45, No. 4. pp. 677-690.
@article{1235b271fd3e45d5b4043d20e18755b1,
title = "Genetic and biochemical normalization in female carriers of duchenne muscular dystrophy: Evidence for failure of dystrophin production in dystrophin-competent myonuclei",
abstract = "Article abstract-We studied 19 symptomatic female carriers of the Duchenne muscular dystrophy (DMD) gene. Most of these dystrophinopathy patients had had an erroneous or ambiguous diagnosis prior to dystrophin immunofluorescence testing. We assessed clinical severity by a standardized protocol, measured X-chromosome inactivation patterns in blood and muscle DNA, and quantitated the dystrophin protein content of muscle. We found that patients could be separated into two groups: those showing equal numbers of normal and mutant dystrophin genes in peripheral blood DNA ({"}random{"} X-inactivation), and those showing preferential use of the mutant dystrophin gene ({"}skewed{"} X-inactivation). In the random X-inactivation carriers, the clinical phenotype ranged from asymptomatic to mild disability, the dystrophin content of muscle was >60{\%} of normal, and there were only minor histopathologic changes. In the skewed X-inactivation patients, clinical manifestations ranged from mild to severe, but the patients with mild disease were young (5 to 10 years old). The low levels of dystrophin (<30{\%} on average) and the severe symptoms of the older patients suggested a poor prognosis for those with skewed X-inactivation, and they all showed morphologic changes of dystrophy. The random inactivation patients showed evidence of biochemical {"}normalization,{"} with higher dystrophin content in muscle than predicted by the number of normal dystrophin genes. Seventy-nine percent of skewed X-inactivation patients (11/14) showed genetic {"}normalization,{"} with proportionally more dystrophin-positive nuclei in muscle than in blood. In 65{\%} of the skewed X-inactivation patients, dystrophin was not produced by dystrophin-positive nuclei; an average of 20{\%} of myofiber nuclei were genetically dystrophin-positive but did not produce stable dystrophin. Biochemical normalization seems to be the main mechanism for rescue of fibers from dystrophin deficiency in the random X-inactivation patients. In the skewed X-inactivation patients, genetic normalization is active, but production failure of dystrophin by dystrophin-normal nuclei may counteract any effect of biochemical normalization. In the skewed X-inactivation patients, the remodeling of the muscle through cycles of degeneration and regeneration led to threefold increase in the number of dystrophin-competent nuclei in muscle myofibers (3.3 +-\4.6), while dystrophin content was on the average 1.5-fold less than expected (-1.54 +-\3.38). Our results permit more accurate prognostic assessment of isolated female dystrophinopathy patients and provide important data with which to estimate the potential effect of gene delivery (gene therapy) in DMD.",
author = "E. Pegoraro and Schimke, {R. N.} and C. Garcia and H. Stern and M. Cadaldini and C. Angelini and E. Barbosa and Carroll, {James Edwin} and Marks, {W. A.} and Neville, {H. E.} and H. Marks and S. Appleton and H. Toriello and Wessel, {H. B.} and J. Donnelly and Bernes, {S. M.} and Taber, {J. W.} and L. Weiss and Hoffman, {E. P.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1212/WNL.45.4.677",
language = "English (US)",
volume = "45",
pages = "677--690",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Genetic and biochemical normalization in female carriers of duchenne muscular dystrophy

T2 - Evidence for failure of dystrophin production in dystrophin-competent myonuclei

AU - Pegoraro, E.

AU - Schimke, R. N.

AU - Garcia, C.

AU - Stern, H.

AU - Cadaldini, M.

AU - Angelini, C.

AU - Barbosa, E.

AU - Carroll, James Edwin

AU - Marks, W. A.

AU - Neville, H. E.

AU - Marks, H.

AU - Appleton, S.

AU - Toriello, H.

AU - Wessel, H. B.

AU - Donnelly, J.

AU - Bernes, S. M.

AU - Taber, J. W.

AU - Weiss, L.

AU - Hoffman, E. P.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Article abstract-We studied 19 symptomatic female carriers of the Duchenne muscular dystrophy (DMD) gene. Most of these dystrophinopathy patients had had an erroneous or ambiguous diagnosis prior to dystrophin immunofluorescence testing. We assessed clinical severity by a standardized protocol, measured X-chromosome inactivation patterns in blood and muscle DNA, and quantitated the dystrophin protein content of muscle. We found that patients could be separated into two groups: those showing equal numbers of normal and mutant dystrophin genes in peripheral blood DNA ("random" X-inactivation), and those showing preferential use of the mutant dystrophin gene ("skewed" X-inactivation). In the random X-inactivation carriers, the clinical phenotype ranged from asymptomatic to mild disability, the dystrophin content of muscle was >60% of normal, and there were only minor histopathologic changes. In the skewed X-inactivation patients, clinical manifestations ranged from mild to severe, but the patients with mild disease were young (5 to 10 years old). The low levels of dystrophin (<30% on average) and the severe symptoms of the older patients suggested a poor prognosis for those with skewed X-inactivation, and they all showed morphologic changes of dystrophy. The random inactivation patients showed evidence of biochemical "normalization," with higher dystrophin content in muscle than predicted by the number of normal dystrophin genes. Seventy-nine percent of skewed X-inactivation patients (11/14) showed genetic "normalization," with proportionally more dystrophin-positive nuclei in muscle than in blood. In 65% of the skewed X-inactivation patients, dystrophin was not produced by dystrophin-positive nuclei; an average of 20% of myofiber nuclei were genetically dystrophin-positive but did not produce stable dystrophin. Biochemical normalization seems to be the main mechanism for rescue of fibers from dystrophin deficiency in the random X-inactivation patients. In the skewed X-inactivation patients, genetic normalization is active, but production failure of dystrophin by dystrophin-normal nuclei may counteract any effect of biochemical normalization. In the skewed X-inactivation patients, the remodeling of the muscle through cycles of degeneration and regeneration led to threefold increase in the number of dystrophin-competent nuclei in muscle myofibers (3.3 +-\4.6), while dystrophin content was on the average 1.5-fold less than expected (-1.54 +-\3.38). Our results permit more accurate prognostic assessment of isolated female dystrophinopathy patients and provide important data with which to estimate the potential effect of gene delivery (gene therapy) in DMD.

AB - Article abstract-We studied 19 symptomatic female carriers of the Duchenne muscular dystrophy (DMD) gene. Most of these dystrophinopathy patients had had an erroneous or ambiguous diagnosis prior to dystrophin immunofluorescence testing. We assessed clinical severity by a standardized protocol, measured X-chromosome inactivation patterns in blood and muscle DNA, and quantitated the dystrophin protein content of muscle. We found that patients could be separated into two groups: those showing equal numbers of normal and mutant dystrophin genes in peripheral blood DNA ("random" X-inactivation), and those showing preferential use of the mutant dystrophin gene ("skewed" X-inactivation). In the random X-inactivation carriers, the clinical phenotype ranged from asymptomatic to mild disability, the dystrophin content of muscle was >60% of normal, and there were only minor histopathologic changes. In the skewed X-inactivation patients, clinical manifestations ranged from mild to severe, but the patients with mild disease were young (5 to 10 years old). The low levels of dystrophin (<30% on average) and the severe symptoms of the older patients suggested a poor prognosis for those with skewed X-inactivation, and they all showed morphologic changes of dystrophy. The random inactivation patients showed evidence of biochemical "normalization," with higher dystrophin content in muscle than predicted by the number of normal dystrophin genes. Seventy-nine percent of skewed X-inactivation patients (11/14) showed genetic "normalization," with proportionally more dystrophin-positive nuclei in muscle than in blood. In 65% of the skewed X-inactivation patients, dystrophin was not produced by dystrophin-positive nuclei; an average of 20% of myofiber nuclei were genetically dystrophin-positive but did not produce stable dystrophin. Biochemical normalization seems to be the main mechanism for rescue of fibers from dystrophin deficiency in the random X-inactivation patients. In the skewed X-inactivation patients, genetic normalization is active, but production failure of dystrophin by dystrophin-normal nuclei may counteract any effect of biochemical normalization. In the skewed X-inactivation patients, the remodeling of the muscle through cycles of degeneration and regeneration led to threefold increase in the number of dystrophin-competent nuclei in muscle myofibers (3.3 +-\4.6), while dystrophin content was on the average 1.5-fold less than expected (-1.54 +-\3.38). Our results permit more accurate prognostic assessment of isolated female dystrophinopathy patients and provide important data with which to estimate the potential effect of gene delivery (gene therapy) in DMD.

UR - http://www.scopus.com/inward/record.url?scp=0028904169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028904169&partnerID=8YFLogxK

U2 - 10.1212/WNL.45.4.677

DO - 10.1212/WNL.45.4.677

M3 - Article

C2 - 7723955

AN - SCOPUS:0028904169

VL - 45

SP - 677

EP - 690

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -